Therefore, miR-138, by the advantage of a BCR-ABL/GATA1/miR-138 integrated circuitry, acts as a tumor suppressor miRNA involved in the pathogenesis of CML and its clinical response to imatinib. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.